Pages that link to "Q36671666"

The following pages link to Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer (Q36671666):

Displaying 23 items.

• Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer (Q33207883) (← links)
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer (Q34001991) (← links)
• Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status (Q34575903) (← links)
• Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer (Q35956595) (← links)
• Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC). (Q35980560) (← links)
• Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. (Q36135604) (← links)
• Epidermal growth factor receptor inhibitors in cancer treatment. (Q36429442) (← links)
• Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? (Q36780626) (← links)
• Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy (Q37347532) (← links)
• Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. (Q37360492) (← links)
• Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer (Q37431620) (← links)
• Gefitinib in the treatment of advanced non-small-cell lung cancer (Q37449013) (← links)
• NSCLC in the elderly--the legacy of therapeutic neglect (Q37486185) (← links)
• Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial (Q37509502) (← links)
• Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. (Q37873453) (← links)
• Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer (Q38594474) (← links)
• Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly (Q38601725) (← links)
• Safety of gefitinib in non-small cell lung cancer treatment (Q38841473) (← links)
• The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC). (Q46254934) (← links)
• Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience (Q46731927) (← links)
• Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience (Q46755113) (← links)
• Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. (Q54582444) (← links)
• Lung cancer (Q81086287) (← links)